RxDoctor Payments Data

Anamika Sharma, MD

Hospitalist · Morristown, NJNPI 1225230345

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 32.3% of the total. Reporting peaked in 2019 at $541 and has fallen 86.6% since, to $72 in 2025. Among hospitalist clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,398in general payments, 2019–2025

Across 60 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$452
  • AbbVie$211
  • Pfizer$203
  • E.r. Squibb & Sons, L.L.C.$186
  • Novo Nordisk$95
  • Cequr Corporation$81
  • plus $170 from 6 others

What the payments were for

  • Food & beverage$1,398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,398 in reported general payments places this provider in the 90th percentile of 567 hospitalist providers in New Jersey.

See all hospitalist providers in New Jersey

Medicare billing

Part B allowed, 2024
$223,253
Medicare patients
641
Services billed
2,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$10,273
Pantoprazole Sodium57$956
CefuroximeCefuroxime Axetil24$360
Albuterol Sulfate HfaAlbuterol Sulfate12$320
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$224
Prednisone28$169
Dexamethasone26$162
Amlodipine Besylate22$112
Cefdinir12$107
Tamsulosin Hcl12$69
Cephalexin13$47
Metoprolol Tartrate13$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$203$10,27317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 567 hospitalist providers in New Jersey.

Other hospitalist in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →